Introduction : As a result of the RAINBOW study, it was found that the OS was extended for Ramucirumab (Ram)+paclitaxel (PTX) combination therapy rather than taxane monotherapy, which was recommended as a secondary treatment for conventional unresectable and recurrent advanced gastric cancer. At the same time, as a result of the REGARD study, Ram monotherapy gained an extension of OS over BSC in the second line treatment. Perpose : We examined the effect of Ram. Patients and Methods : 50 patients used in our hospital since June 2015. Male 38, 12 females, median age at onset was 69 years old. Ram/PTX combined use (RP group) 45, Ram alone (R group) 5 cases. Treatment results and adverse events of RP group and R group were examined. Results : The median observation period after Ramucirumab started was 269 days. The median effective value was 5 courses in the RP group and 157 days in the PFS.RP group was 1st line: 4, 2nd line: 36, 3rd line: 4 cases, 4th line: 1 case, R group was 2nd line: 2 cases, 3rd, 4th and 5th line were each one case. case. Response rate of RP group was 28% and DCR was 72%. Hematotoxicity of Gr.3≦ was 36% in leukopenia, 43% in neutropenia, 11% in thrombocytopenia and 4% in FN. Non - hematologic toxicity was associated with Ram in 1 case of gastric perforation G4, but all others were Gr.2≧. PTX related Gr.3≦ had peripheral neuropathy 4%, fatigue 16%, hyperbilirubinemia 4%, appetite reduction 8%. Dose intensity was median Ram 100%, PTX 76%. Conclusion : Ramucirumab is considered to be an agent that can manage adverse events well and can be expected sufficiently in clinical practice.